Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to be effective in the treatment of type 2 diabetes while improving the end-stage outcome of DN (Zhang et al., 2023; Chen et al., 2023; Prattichizzo, de Candia & Ceriello, 2021). Here, SLC5A2 is linked to liver dysplastic nodule.